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Peter Libby, MD, Robert Roberts, MD, Eva van Rooij, PHD, Gordon Tomaselli, MD, L. Kristin Newby, MD, MHST he Editors are pleased to present the inau-gural edition of JACC: Basic to TranslationalScience. Given the recent proliferation of
journals, especially subspecialty cardiovascular jour-
nals, it is appropriate to question the need for a jour-
nal dedicated to bringing the fruits of fundamental
scientiﬁc discoveries to patients. We ﬁnd 2 compel-
ling reasons to develop a journal that focuses on the
critical interface between laboratory and clinical sci-
ence. First, although a number of outstanding jour-
nals publish elegant scientiﬁc studies that seek to
extend their ﬁndings in human biological samples,
or that publish studies on novel devices or discov-
eries that can enter clinical trials, there has never
been a scientiﬁc literary home for cardiovascular
“translationalists” who wish to publish research that
stands ﬁrmly at the crossroads of basic and clinical
research. We do not seek to publish research that
recapitulates the types of scientiﬁc studies that are
published in existing high-impact scientiﬁc journals;
rather, we will endeavor to publish those scientiﬁc
studies that will lead to new therapies. More estab-
lished journals often quickly dismiss translational
studies for perceived lack of mechanistic depth and/
or because they involve too few patients to engender
conﬁdence that phase III clinical trials will validate
the ﬁndings. As Editors, we recognize the inherent
fragility of new ideas, and believe ﬁrmly that new
ideas cannot grow to become new therapies unless
they see light of day. One cannot move to phase III
clinical trials without passing through smaller phase
I and II studies. These smaller clinical trials merit
expeditious publication by a balanced and rigorous
editorial process, and editors unafraid to publish
these studies or innovative concepts, despite their
exploratory nature.The second, and perhaps more compelling, reason
to launch a journal that focuses on cardiovascular
translational science is the unprecedented opportu-
nity today to develop novel cardiovascular drugs
and devices. The explosion of “omic” technologies,
bioinformatics, in silico structure modeling, high
throughput screening, and novel clinical designs, and
the willingness of Congress to advance new clinical
therapies through the 21st Century Cures Act, have
converged to offer an extremely opportune time for
investigators to focus their efforts on developing new
cardiovascular therapies. Translational science ex-
empliﬁes “big science,” because it requires effective
cooperation between basic and clinical investigators
in academia and industry, patients and their families,
patient advocacy groups, and governmental funding
and regulatory agencies to evaluate and develop new
therapies. No one person can possibly acquire all
the requisite skills needed to conduct this type of
research, and no one individual can move their ideas
forward in the cardiovascular space unaided. JACC:
Basic to Translational Science seeks to become both a
forum and a learning center for cardiovascular in-
vestigators in academia and industry, patients and
families impacted by heart disease, the National
Heart, Blood, and Lung Institute, and the U.S. Food
and Drug Administration to help advance trans-
lational cardiovascular medicine. We aim to create an
open access journal that will serve as a platform
for accelerating the translation of new scientiﬁc
discoveries into new therapies that improve clinical
outcomes for patients afﬂicted with or at risk
for cardiovascular disease. Although we recognize
that attaining a high-impact factor has become a
customary de facto goal for scientiﬁc journals, we will
measure our long-term success by the number of new
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2therapies and/or translational avenues ﬁrst explored
in JACC: Basic to Translational Science.
The Editors realize that in an effort to cover the
entire breadth of the translational cardiovascular
research space, from new molecules and devices, to
animal models, to early-phase transitional trials, we
run the risk of creating a journal that becomes a
scholarly jack-of-all-trades, yet master of none. As
Editors, we remain committed to publishing the
highest quality translational science, which by its
nature means taking some risks on new ideas
and early-phase discoveries. Accordingly, we recog-
nize that we may occasionally overreach in our
enthusiasm to advance new therapies. For this
reason, we welcome comments and suggestions frominvestigators in academia and industry, patients,
societies, and all of the governmental regulatory
agencies to assist us as we endeavor to guide the
Journal toward fulﬁlling its promise of improving
outcomes for patients afﬂicted with cardiovascular
disease.
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